Article Sidebar

Submitted
Feb 19, 2023
Published
Feb 19, 2023
Download
PDF
Statistic
Read Counter : 86 Download : 72

Main Article Content

Abstract

BACKGROUND: Rheumatoid arthritis [RA] is a chronic inflammatory disease characterized by progressive joint erosion, resulting in significant disability, morbidity and increased mortality. The introduction of DMARDs in the treatment of rheumatic diseases over the last two decades has significantly improved clinical outcomes. Disease modifying anti-rheumatic drugs [DMARDs] is a group of drugs that slow or stop the immune system from destroying the joints. These agents can retard or prevent disease progression and thus joint destruction and subsequent loss of function. All DMARDs show significant toxicity, such that their use requires regular monitoring.
OBJECTIVES: To identify and evaluate the drug related Side effects with the use of DMARD’s in RA patients. To establish role of pharmacist to minimize side effects with DMARDs.

METHODS: A prospective study was conducted on the use of DMARDs and their Side effects. Data was collected between January 2021 – July 2021 from orthopedic and rheumatology clinics within the hospital from out-patient department. The data collected was entered in a data collection form designed for the purpose and included all the required parameters. The obtained information was used to understand the side effects of DMARDs.


RESULTS: In our study 65% of the patients reported side effects and other 35% of the patients didn’t have any side effects. In females, age group of 51-60 were mostly affected with RA than other age groups where as in males age group of 41-50 were mostly affected. Other side effects reported in patients taking DMARDs include Vomiting, Acidity, Fever, Dizziness, Dyspepsia, Swelling of tongue, Pigmentation of skin, Insomnia, Blurred vision and increased Appetite.


CONCLUSION: The side effects associated with disease modifying anti rheumatoid drugs in rheumatoid arthritis patients were found to be significant. Out of 40 patients, 26 reported side effects and other 14 didn’t have were stable without any side effects. 7 reported Stomachache, 8 reported Dryness of mouth and 11 patients reported other side effects. Among other side effects vomiting and acidity were more commonly reported.

Keywords

DMARDs, Rheumatoid arthritis, Side effects

Article Details

How to Cite
J. Anantha Lakshmi, K. Ramya Sree, J. Sri Nitya, Prabhath Lakkireddy, N. Anusha, & Yeshwanth Varma. (2023). A prospective study to monitor the side effects associated with disease modifying anti rheumatoid drugs in out-patients of tertiary care hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics, 12(1), 1-7. https://doi.org/10.61096/ijrpp.v12.iss1.2023.1-7
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094-9. doi: 10.1136/ard.2008.092668, PMID 19033290.
  2. 2. Katzung B, Masters S. Trevor A. Basic & Clinical Pharmacology. 12th ed. McGraw-Hill Companies, Inc; 2015.
  3. 3. McKenzie G. AH, Scherbel AL. Chloroquine and hydroxychloroquine in rheumatologi- Cal therapy. Clin Rheum Dis. 1980;6:545-66.
  4. 4. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am. 2009;35(4):745-57. doi: 10.1016/j.rdc.2009.10.001, PMID 19962619.
  5. 5. Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(6):1460-9. doi: 10.1002/art.10307, PMID 12115175.
  6. 6. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52Â week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58(4):220-5. doi: 10.1136/ard.58.4.220, PMID 10364900.
  7. 7. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285-93. doi: 10.1136/ard.2005.038638, PMID 16107513.
  8. 8. Cronstein BN. Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57(2):163-72. doi: 10.1124/pr.57.2.3, PMID 15914465.
  9. 9. Alcorn N, Capell H, Madhok R, Madhok R. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol. 2007 Aug;3(8):450-8 [quiz], following 478. doi: 10.1038/ncprheum0562, PMID 17664952.
  10. 10. van Hunsel F, de Jong E, Gross-Martirosyan L, Hoekman J. Signals from the Dutch national spontaneous reporting system: characteristics and regulatory actions. Pharmacoepidemiol Drug Saf. 2021;30(8):1115-22. doi: 10.1002/pds.5246, PMID 33840136.
  11. 11. Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease‐ modifying anti-rheumatic drugs in clinical practice. QJM An Int J Med. 2001;94(6, Jun):309-19. doi: 10.1093/qjmed/94.6.309, PMID 11391029.
  12. 12. Nozaki Y, Inoue A, Kinoshita K, Funauchi M, Matsumura I. Efficacy of iguratimod vs. salazosulfapyridine as the first-line csDMARD for rheumatoid arthritis. Mod Rheumatol. 2020;30(2):249-58. doi: 10.1080/14397595.2019.1572267, PMID 30676812.
  13. 13. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol. 2012;39(8):1559-82. doi: 10.3899/jrheum.110207, PMID 21921096.
  14. 14. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatol (Oxf Engl). 2011;50(1):124-31. doi: 10.1093/rheumatology/keq242, PMID 20675706.
  15. 15. Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor—αblocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatol (Oxf Engl). 2007;46(2):327-34. doi: 10.1093/rheumatology/kel236, PMID 16880188.
  16. 16. Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol. Oct 2004;31(10):1906-11. PMID 15468352.
  17. 17. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T et al. Safety and effectiveness of 6 months’ etanercept monotherapy and combination therapy in Japanese patients with rheumatoid arthritis: effect of concomitant disease-modifying antirheumatic drugs. J Rheumatol. Oct 2013;40(10):1658-68. doi: 10.3899/jrheum.120490, PMID 23908446.